Erastin联合Tubacin促进乳腺癌HCC38细胞死亡
Erastin plus Tubacin Treatment Promotes Breast Cancer Cell Death of HCC38
DOI: 10.12677/ACM.2023.1351221, PDF,    科研立项经费支持
作者: 吴灿章*, 敬 波, 郑武平, 吴煌福#:海南医学院第二附属医院甲乳外科,海南 海口
关键词: 三阴型乳腺癌细胞死亡TubacinErastinTriple Negative Breast Neoplasms Cell Death Tubacin Erastin
摘要: 目的:根据表观遗传特征,可以对恶性肿瘤进行分型,并针对分子异常代谢给予精准打击,实现抗肿瘤目的,这是一种新兴治疗策略。在多数细胞恶变过程中,胱氨酸的成瘾是常见的异常代谢。随后,Erastin被研究者发现,它能抑制胱氨酸谷氨酸转运体(Xc-system),从而诱导细胞死亡。对大多数乳腺癌效果显著。然而,三阴型乳腺癌细胞是非间充质的,对Erastin治疗无反应。为了克服这种耐药性,我们筛选并鉴定出Tubacin,它可以转变恶性肿瘤的胱氨酸不敏感的状态。为了验证Tubacin实际效果,我们尝试在Tubacin、Erastin条件下处理三阴型乳腺癌细胞,对比观察细胞死亡实际情况。方法:本研究的三阴型乳腺癌细胞株HCC38购自ATCC公司,在DMSO、Tubacin、Erastin、及Erastin联合Tubacin条件下进行处理,以流式细胞学等方式检测细胞死亡。结果:1) 单独使用Tubaicn、Erastin处理HCC38细胞,细胞死亡幅度无明显变化。2) Erastin联合Tubacin处理癌细胞可以显著诱导死亡。3) 与DMSO、Tub、Era相比,Era + Tub组别细胞死亡明显增多。4) 与DMSO相比,Tub、Era、Era + Tub组别细胞的活性氧均不同程度增高,后两者显著增高。结论:Erastin联合Tubacin可促进乳腺癌HCC38细胞死亡。
Abstract: Purpose: According to epigenetic features, malignant tumors can be typed and given a precise blow against the molecular aberrant metabolism, achieving antitumor purpose, which is an emerging therapeutic strategy. Addiction to cystine is the more common aberrant metabolism involved in most cellular malignant transformation. Subsequently, the cystine blocker erastin was discovered to inhibit the cystine glutamate transporter (XC-System), which induces cell death and has pro-duced significant effect against most breast cancers. However, TNBC cells are non mesenchymal and do not respond to cystine deprivation treatment. To overcome this resistance, we screened and identified tubacin, which can transform the cystine insensitive state of malignancies. To verify the actual effect of tubacin, we tried to treat triple negative breast cancer cells under tubacin, erastin conditions and observed the cell death reality comparatively. Methods: The triple negative breast cancer cell line HCC38 from this study was purchased from ATCC and treated in DMSO, Tubacin, Erastin, and Erastin plus Tubacin to detect cell death by flow cytometry. Results: 1) In HCC38 cells treated with tubaicn or erastin alone, the magnitude of cell death was unchanged. 2) Treatment of cancer cells with erastin in combination with tubacin significantly induced death. 3) Compared with DMSO, Tub, or Era, cell death was significantly increased in the Erastin plus Tubacin Group. 4) Compared with DMSO, ROS increased in all cell lines in the Tub, Era, and Erastin plus Tubacin groups, and the latter two were significantly higher. Conclusions: Erastin, in combination with tuba-cin, confers breast cancer cells death of HCC38.
文章引用:吴灿章, 敬波, 郑武平, 吴煌福. Erastin联合Tubacin促进乳腺癌HCC38细胞死亡[J]. 临床医学进展, 2023, 13(5): 8733-8740. https://doi.org/10.12677/ACM.2023.1351221

参考文献

[1] Garrido-Castro, A.C., Lin, N.U. and Polyak, K. (2019) Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discovery, 9, 176-198. [Google Scholar] [CrossRef
[2] Jiang, Y.Z., Ma, D., Suo, C., et al. (2019) Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell, 35, 428-440. [Google Scholar] [CrossRef] [PubMed]
[3] Cho, B., Han, Y., Lian, M., et al. (2019) Evaluation of Racial/Ethnic Differences in Treatment and Mortality among Women with Triple-Negative Breast Cancer. JAMA Oncolo-gy, 7, 1016-1023.
[4] Poggio, F., Bruzzone, M., Ceppi, M., et al. (2018) Platinum-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Annals of Oncology, 29, 1497-1508. [Google Scholar] [CrossRef] [PubMed]
[5] Lyons, T.G. (2019) Targeted Therapies for Triple-Negative Breast Cancer. Current Treatment Options in Oncology, 20, Article No. 82. [Google Scholar] [CrossRef] [PubMed]
[6] Wu, S.Y., Xu, Y., Chen, L., et al. (2022) Combined Angiogenesis and PD-1 Inhibition for Immunomodulatory TNBC: Concept Exploration and Biomarker Analysis in the FUTURE-C-Plus Trial. Molecular Cancer, 21, Article No. 84. [Google Scholar] [CrossRef] [PubMed]
[7] Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674. [Google Scholar] [CrossRef] [PubMed]
[8] Hainaut, P. and Plymoth, A. (2013) Targeting the Hallmarks of Cancer: Towards a Rational Approach to Next- Generation Cancer Therapy. Current Opinion in Oncology, 25, 50-51. [Google Scholar] [CrossRef
[9] Sui, S., Xu, S. and Pang, D. (2022) Emerging Role of Fer-roptosis in Breast Cancer: New Dawn for Overcoming Tumor Progression. Pharmacology & Therapeutics, 232, Article ID: 107992. [Google Scholar] [CrossRef] [PubMed]
[10] Song, C.W., Clement, J.J. and Levitt, S.H. (1976) Preferen-tial Cytotoxicity of 5-Thio-D-glucose against Hypoxic Tumor Cells. JNCI: Journal of the National Cancer Institute, 57, 603-605. [Google Scholar] [CrossRef] [PubMed]
[11] Badgley, M.A., Kremer, D.M., Maurer, H.C., et al. (2020) Cysteine Depletion Induces Pancreatic Tumor Ferroptosis in Mice. Science, 368, 85-89. [Google Scholar] [CrossRef] [PubMed]
[12] Xu, T., Ding, W., Ji, X., et al. (2019) Molecular Mechanisms of Ferroptosis and Its Role in Cancer Therapy. Journal of Cellular and Molecular Medicine, 23, 4900-4912. [Google Scholar] [CrossRef] [PubMed]
[13] Schonberg, D.L., Miller, T.E., Wu, Q., et al. (2015) Preferential Iron Trafficking Characterizes Glioblastoma Stem- Like Cells. Cancer Cell, 28, 441-455. [Google Scholar] [CrossRef] [PubMed]
[14] Chen, M.S., Wang, S.F., Hsu, C.Y., et al. (2017) CHAC1 Degra-dation of Glutathione Enhances Cystine-Starvation- Induced Necroptosis and Ferroptosis in Human Triple Negative Breast Cancer Cells via the GCN2-eIF2α-ATF4 Pathway. Oncotarget, 8, 114588-114602. [Google Scholar] [CrossRef] [PubMed]
[15] Yang, W.S., SriRamaratnam, R., Welsch, M.E., et al. (2014) Regu-lation of Ferroptotic Cancer Cell Death by GPX4. Cell, 156, 317-331. [Google Scholar] [CrossRef] [PubMed]
[16] Bansal, A. and Simon, M.C. (2018) Glutathione Metabolism in Cancer Progression and Treatment Resistance. Journal of Cell Biology, 217, 2291-2298. [Google Scholar] [CrossRef] [PubMed]
[17] Tang, X., Ding, C.K., Wu, J., et al. (2017) Cystine Addiction of Tri-ple-Negative Breast Cancer Associated with EMT Augmented Death Signaling. Oncogene, 36, 4235-4242. [Google Scholar] [CrossRef] [PubMed]
[18] Rodenhiser, D.I. andrews, J., Kennette, W., et al. (2008) Epigenetic Mapping and Functional Analysis in a Breast Cancer Metastasis Model Using Whole-Genome Promoter Tiling Microar-rays. Breast Cancer Research, 10, R62. [Google Scholar] [CrossRef] [PubMed]
[19] Komatsu, S., Moriya, S., Che, X.F., et al. (2013) Combined Treatment with SAHA, Bortezomib, and Clarithromycin for Concomitant Targeting of Aggresome Formation and Intracellular Proteolyt-ic Pathways Enhances ER Stress- Mediated Cell Death in Breast Cancer Cells. Biochemical and Biophysical Research Communications, 437, 41-47. [Google Scholar] [CrossRef] [PubMed]
[20] Namdar, M., Perez, G., Ngo, L., et al. (2010) Selective Inhibition of Histone Deacetylase 6 (HDAC6) Induces DNA Damage and Sensitizes Transformed Cells to Anticancer Agents. Proceedings of the National Academy of Sciences of the United States of America, 107, 20003-20008. [Google Scholar] [CrossRef] [PubMed]
[21] Li, T., Zhang, C., Hassan, S., et al. (2018) Histone Deacetylase 6 in Cancer. Journal of Hematology & Oncology, 11, Article No. 111. [Google Scholar] [CrossRef] [PubMed]
[22] Feinberg, A.P. (2007) Phenotypic Plasticity and the Epigenetics of Human Disease. Nature, 447, 433-440. [Google Scholar] [CrossRef] [PubMed]
[23] Elsheikh, S.E., Green, A.R., Rakha, E.A., et al. (2009) Global Histone Modifications in Breast Cancer Correlate with Tumor Phenotypes, Prognostic Factors, and Patient Outcome. Cancer Re-search, 69, 3802-3809. [Google Scholar] [CrossRef
[24] Lee, S.W., Yeon, S.K., Kim, G.W., et al. (2021) HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma. International Journal of Molecular Sciences, 22, Article 1341. [Google Scholar] [CrossRef] [PubMed]
[25] Yu, S., Cai, X., Wu, C., et al. (2017) Targeting HSP90-HDAC6 Regu-lating Network Implicates Precision Treatment of Breast Cancer. International Journal of Biological Sciences, 13, 505-517. [Google Scholar] [CrossRef] [PubMed]
[26] Marcus, A.I., Zhou, J., O’Brate, A., et al. (2005) The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase. Cancer Research, 65, 3883-3893. [Google Scholar] [CrossRef
[27] Aldana-Masangkay, G.I., Rodriguez-Gonzalez, A., Lin, T., et al. (2011) Tubacin Suppresses Proliferation and Induces Apoptosis of Acute Lymphoblastic Leukemia Cells. Leukemia & Lymphoma, 52, 1544-1555. [Google Scholar] [CrossRef] [PubMed]
[28] Zuo, Q., Wu, W., Li, X., et al. (2012) HDAC6 and SIRT2 Promote Bladder Cancer Cell Migration and Invasion by Targeting Cortactin. Oncology Reports, 27, 819-824.
[29] Kim, C., Gao, R., Sei, E., et al. (2018) Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. Cell, 173, 879-893.e13. [Google Scholar] [CrossRef] [PubMed]
[30] Romayor, I., García-Vaquero, M.L., Márquez, J., et al. (2022) Discoidin Domain Receptor 2 Expression as Worse Prognostic Marker in Invasive Breast Cancer. The Breast Journal, 2022, Article ID: 5169405. [Google Scholar] [CrossRef] [PubMed]
[31] Wu, C., Ying, J., Dai, M., Peng, J., et al. (2022) Co-Expression of DDR2 and IFITM1 Promotes Breast Cancer Cell Proliferation, Migration and Invasion and Inhibits Apoptosis. Journal of Cancer Research and Clinical Oncology, 148, 3385-3398. [Google Scholar] [CrossRef] [PubMed]
[32] Brown, R., Curry, E., Magnani, L., et al. (2014) Poised Epige-netic States and Acquired Drug Resistance in Cancer. Nature Reviews Cancer, 14, 747-753. [Google Scholar] [CrossRef] [PubMed]
[33] Dworkin, A.M., Huang, T.H. and Toland, A.E. (2009) Epigenetic Alterations in the Breast: Implications for Breast Cancer Detection, Prognosis and Treatment. Seminars in Cancer Biology, 19, 165-171. [Google Scholar] [CrossRef] [PubMed]
[34] Zhao, Y., Li, Y., Zhang, R., et al. (2020) The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy. OncoTargets and Therapy, 13, 5429-5441. [Google Scholar] [CrossRef
[35] Hao, H., Cao, L., Jiang, C., et al. (2017) Farnesoid X Receptor Regula-tion of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis. Cell Metabolism, 25, 856-867.e5. [Google Scholar] [CrossRef] [PubMed]
[36] Zheng, D., Liu, J., Piao, H., et al. (2022) ROS-Triggered Endothe-lial Cell Death Mechanisms: Focus on Pyroptosis, Parthanatos, and Ferroptosis. Frontiers in Immunology, 13, Article ID: 1039241. [Google Scholar] [CrossRef] [PubMed]